Leaders in Life Sciences – #1 Clémence Ross
Clémence Ross is ambassadeur voor het Actieprogramma ‘Nieuwe kansen voor Topsector Life Sciences & Health’ (LSH) van het ministerie van Economische Zaken en Klimaat.
20 May 2022
Leaders in Life Sciences – #1 Clémence Ross
Clémence Ross is ambassadeur voor het Actieprogramma ‘Nieuwe kansen voor Topsector Life Sciences & Health’ (LSH) van het ministerie van Economische Zaken en Klimaat.
Glycostem announces new data presentation highlighting early safety and clinical course of oNKord® in patients with Acute Myeloid Leukemia
CEO RiboPro elected most promising entrepreneur of the year.
Sander van Asbeck, CEO and co-founder of RiboPro has been elected most promising entrepreneur of the year 2022. With his company, he develops messenger RNA technology for the development of new medical treatments.
Oss and Montreal, February 14, 2022. InProcess-LSP and Spectra Research Corporation (SRC) are pleased to announce they have entered into a partnership, combining SRC’s industry-leading market knowledge with InProcess’s world class and groundbreaking nanoparticle sizing technology delivering unique solutions for the particle characterization markets.
IPA is pleased to announce that it has completed its previously announced acquisition of control over BioStrand BV, BioKey BV, and BioClue BV, a group of Belgian biotech entities and pioneers in the field of bioinformatics and biotechnology, through its wholly owned subsidiary ImmunoPrecise Netherlands BV.
Gimv treedt toe als nieuwe investeerder in BioConnection met als doel de volgende groeifase van de onderneming te financieren en ondersteunen.
Open gesprekken met leiders in life sciences, Pivot Park initieert podcastserie.
Op Pivot Park ontwikkelen ze veel meer dan geneesmiddelen. Met Leaders in Life Sciences draagt het Osse life sciences park vandaag bij aan de lancering van een podcastserie.
T cell acute lymphoblastic leukemia (T-ALL) is an aggressive cancer arising from aberrant proliferation of T cell progenitors and accounts for 15% of pediatric ALL cases. Current standard treatment, consisting of high-dose multiagent chemotherapy, has led to an overall survival rate exceeding 80%. Nevertheless, one out of five children with T-ALL will relapse within four years after the start of therapy. New treatment options are urgently needed.
Expat program for international community members
Moving to another country is a big step and an exciting time for expats. How do you make sure your international newcomers feel at home, meet others, understand their Dutch environment and colleagues better and enjoy their new lives in the Netherlands even more?
BioConnection returns 20,000 euros at symbolic conclusion of employment project
Pharmaceutical company BioConnection returned a check containing 20,000 euros of MSD money on Thursday, March 31. That symbolic step marks the provisional end of a program that was intended to boost employment in Oss.
The development of medicines in Oss began one hundred years ago. It was then that the foundations were laid for what would become a flourishing pharmaceutical sector in the Netherlands, leading to groundbreaking discoveries such as insulin and the anti-conception pill.
Today, the entire chain is still represented in Oss, from early-stage research to the commercial scale production of medicines. Working in Oss, we focus on the health of people all over the world. Employees at dozens of companies large and small put their heart and soul into new medicines, products and services that will improve lives worldwide. Together, our strength lies in our combination of broad knowledge about the development of medicines and a thorough understanding of the requirements of high-quality production.
This shared past and common values stimulate strong bonds among everyone who works in pharmaceuticals in Oss. We build on qualities, expertise and networks that go back decades. And with a wide variety of pharmaceutical companies, suppliers and scientific institutions all located nearby, we offer an attractive business climate and an excellent basis for international collaboration.
We are proud to work together to create a better and healthier future for all, a collaboration that in turn fuels growing employment: today, most pharmaceutical jobs in the Netherlands are in Oss. Here we connect talent and companies and stimulate entrepreneurship, while our expert employees are our most important asset. Their drive ensures that Oss has an influence on health all over the world.
Pharma in Oss offers endless opportunities to startups and talent in a city and region that is a joy to live and work in. We are committed to collaboration and sustainable and successful entrepreneurship. Oss’s pharmaceutical companies are intrinsically competitive while also being committed to quality and safety. This, plus their focus on new health solutions and contemporary technology, makes us a leader in our pursuit of a better life for people worldwide.